Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma

Modern Pathology

Volumn 9, Issue 5, 1996, Pages 544-554

  Gorgoulis, Vassilis G ^a   Rassidakis, George Z ^a   Karameris, Andreas M ^a   Papastamatiou, Hera ^a   Trigidou, Rodoula ^a   Veslemes, Marinos ^a   Rassidakis, Antonis N ^a   Kittas, Christos ^a  

^a NONE

Author keywords

Differential PCR; Immunohistochemistry; Lung carcinoma; mdm 2 protein; Northern blot; p53 protein; SSCP

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

ADENOCARCINOMA; AGED; BLOTTING, NORTHERN; CARCINOMA, BRONCHOGENIC; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029891010     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 75: 191, 1995
2. Souhami LR: The antigens of lung cancer. In New Perspectives in Lung Cancer, edited by Thatcher N, Spiro S, p 68. London, BMJ Publishing Group, 1994
3. Gazdar AF: The molecular and cellular basis of human lung cancer. Anticancer Res 14:261, 1994
4. Kalemkarian PG: Biology of lung cancer. Curr Opin Oncol 6:147, 1994
5. Anderson MLM, Spandidos DA: Oncogenes and onco-suppressor genes in lung cancer. Respir Med 87:413, 1993
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855, 1994
7. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453, 1991
8. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523, 1992
9. Zambetti GP, Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855, 1993
10. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237, 1992
11. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 13:235, 1987
12. Oliner GD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80, 1992
13. Haines DL, Landers JE, Engle LJ, George DL: Physical, functional interaction between wild-type p53 and mdm-2 proteins. Mol Cell Biol 14:1171, 1994
14. Finlay C: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301, 1993
15. Leach FS, Tokino T, Meltzer P, et al.: p53 mutation and mdm-2 amplification in human soft tissue sarcomas. Cancer Res 53:2231, 1993
16. Ladanyi M, Cha C, Lewis R, et al.: mdm-2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16, 1993
17. Reifenberger G, Liu L, Ichimura K, Schmidt E, Collins V: Amplification and overexpression of mdm-2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736, 1993
18. Marchetti A, Buttitta F, Girlando S, et al.: mdm-2 gene alterations and mdm-2 protein expression in breast carcinomas. J Pathol 175:31, 1995
19. Buesco-Ramos CE, Yang Y, deLeon E, et al.: The human mdm-2 oncogene is overexpressed in leukemias. Blood 82: 2617, 1993
20. Watanabe T, Hotta T, Ichikawa A, et al.: The mdm-2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158, 1994
21. Wiethege T, Voss B, Muller KM: Detection of mdm-2-protooncogene in paraffin embedded human bronchial epithelium. J Cancer Res Clin Oncol 124:252, 1994
22. World Health Organization: The World Health Organization histologic typing of lung tumors. Am J Clin Pathol 77:123, 1982
23. Mountain CF: The new international staging system for lung cancer. Surg Clin North Am 67:925, 1987
24. Auerbach O, Gere GB, Forman JB, et al: Changes in the bronchial epithelium in reaction to smoking and cancer of the lung. N Engl J Med 256:97, 1957
25. Norton AJ, Jordan S, Yeomans P: Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173:371, 1994
26. Gorgoulis V, Rassidakis G, Karameris A, et al.: Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: Possible correlation with human papillomavirus infection and clinicopathological findings. Virchows Arch 425: 481, 1994
27. Sambrook J, Fritsh EF, Maniatis T: Molecular Cloning. A Laboratory Manual. Plainview, NY, Cold Spring Harbor Laboratory, 1989
28. Gorgoulis V, Barbatis C, Poulias I, Karameris A: Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients. Mod Pathol 8:758, 1995
29. Fontana X, Ferrari Abbes M, Monticelli Namer M, Bussiere F: Etude de l'amplification du gene mdm-2 dans les tumeurs primitives du cancer du sein. Bull Cancer 81:587, 1994
30. Gorgoulis V, Zoumpourlis V, Rassidakis G, et al.: Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions: p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Arch 426:339, 1995
31. Marchetti A, Buttitta F, Merlo G, et al: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of the hilar and mediastinal lymph nodes. Cancer Res 53:2846, 1993
32. Maxwell SA: Selective compartmentalization of different mdm-2 proteins within the nucleus. Anticancer Res 14:2541, 1994
33. Ofner D, Maier H, Riedmann B, et al.: Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: Prognostic significance. J Clin Pathol Mol Pathol 48:M12, 1995.
34. Chilosi M, Doglioni C, Menestrina F, et al.: Abnormal expression of the p53 binding protein mdm-2 in Hodgkin's disease. Blood 84:4295, 1994
35. Olson D, Marechal V, Momand J, et al.: Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8:2353, 1993
36. Wu X, Bayle JH, Olson D, Levine AJ: The p53- mdm-2 auto-regulatory feedback loop. Genes Dev 7:1126, 1993
37. Price BD, Park SJ: DNA damage increases the levels of mdm-2 messenger RNA in wtp53 human cells. Cancer Res 54:896, 1994
38. Waber PG, Chen J, Nisen DP: Infrequency of mdm-2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53:6028, 1993
39. Hall AP, Lane PD: p53 in tumor pathology: Can we trust immunohistochemistry? Revisited. J Pathol 162:5, 1994
40. El-Deiry WS, Tokino T, Velculescu VE, et al.: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
41. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675, 1990
42. Caron de Fromentel C, Soussi T: p53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosom Cancer 4:1, 1992
43. Bankfalvi A, Navabi H, Bier B, et al.: Wet autocleave pretreatment for antigen retrieval in diagnostic immunocytochemistry. J Pathol 174:223, 1994
44. Baas IO, Mulder JWR, Offerhaust JA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5, 1994
45. Karameris AM, Worthy E, Gorgoulis VG, Quezados M, Anastassiades OT: p53 gene alterations in species types of breast carcinoma: A molecular and immunohistochemical study in archival material. J Pathol 176:361, 1995
46. Bennett WP, Colby TV, Travis WT, et al: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817, 1993
47. Dosaka-Akita H, Shindoh M, Fujino M, et al.: Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 102:660, 1994
48. Brambilla E, Gazzeri S, Moro D, et al.: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199, 1993
49. Korkolopoulou P, Oates J, Crocker J, Edwards C: p53 expression in oat and non-oat small cell lung carcinomas: Correlations with proliferating cell nuclear antigen. J Clin Pathol 46:1093, 1993
50. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Proc Natl Acad Sci U S A 5:874, 1989
51. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 86:2766, 1989
52. Melhem M, Law J, El-Ashmawy L, et al.: Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 146:1170, 1995
53. Bodner SM, Minna JD, Jensen SM, et al.: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743, 1992
54. Costa A, Marasca R, Valentinis B, et al.: p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176:45, 1995
55. Zhan Q, Bae I, Kastan MB, Fornace AJ: The p53-dependent-x-ray response of GADD45. Cancer Res 54:2755, 1994
56. Dittmer D, Parti S, Zambetti G, et al.: Gain of function mutations in p53. Nat Genet 4:42, 1993
57. Park DJ, Nakamura H, Chumakov AM, et al.: Transactivational and DNA binding abilities of endogenous p53 mutant cell lines. Oncogene 9:1899, 1994
58. Niewolik D, Vojtesek B, Kovarik J: p53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881, 1995
59. Deb S, Jackson CT, Subler MA, Martin DW: Modulation of cellular and viral promoters by mutant human p53 promoters found in tumor cells. J Virol 66:6170, 1992
60. Miller CW, Simon K, Aslo A, et al.: p53 mutations in human lung tumors. Cancer Res 52:1695, 1992
61. Baker S, Presinger A, Jessup J, et al.: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717, 1990
62. Harvey M, Vogel H, Morris D, et al.: A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305, 1995
63. Cordon-Cardo C, Latres E, Drobnjak M, et al.: Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794, 1994
64. Martinez JC, Mateo M, Sanchez-Beato M, et al.: mdm-2 expression in lymphoid cells and reactive neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 177:27, 1995